Survodutide

The FDA has granted breakthrough therapy designation to Boehringer Ingelheim’s survodutide for the treatment of adult patients with noncirrhotic metabolic dysfunction-associated steatohepatitis and moderate or advanced fibrosis.

Survodutide was superior to placebo and significantly improved markers of metabolic dysfunction-associated steatohepatitis without worsening of fibrosis, according to data presented at EASL Congress.

WASHINGTON — Survodutide sustained improvement in liver fat content, liver enzymes and fibrosis biomarkers in patients with metabolic dysfunction-associated steatohepatitis at 28 weeks, according to a late-breaking abstract presented here.

A slew of new medications currently in development may allow health care providers to go beyond glycemic management in the treatment of type 2 diabetes, according to a speaker.

Adults with obesity can lose 15% or more of their body weight with nutrient-stimulated hormone-based therapies, but reducing body weight is not the only goal providers should have when treating obesity, according to a speaker.

DALLAS — In this Healio video exclusive, Ania M. Jastreboff, MD, PhD, highlights several medications that may have a large impact on obesity care in the near future.

SAN DIEGO — Adults with overweight or obesity lost up to 18.7% of their body weight at 46 weeks with a glucagon/GLP-1 dual agonist, according to a speaker.